Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of Major Bleeding at 18 Months: Secondary Prevention (Balanced) Cohorts
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.142 | 0.135 | 0.15 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.111 | 0.105 | 0.116 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | 0.0318 | 0.0222 | 0.0415 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 1.29 | 1.19 | 1.39 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 1.34 | 1.23 | 1.46 | log | ClinicalTrials.gov | |
| Number needed to treat, for one more participant with the outcome on Secondary Prevention Cohort (Balanced): Apixaban than on Secondary Prevention Cohort (Balanced): Warfarin | 31.5 | 24.1 | 45 | from the risk difference interval | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Secondary Prevention Cohort (Balanced): Apixaban | Participants with prior diagnosis of stroke who were newly diagnosed with NVAF and initiated apixaban on the index date and were balanced using sIPTW method. | 1,110 | 7,796 | OG000 | ClinicalTrials.gov |
| Group 2 | Secondary Prevention Cohort (Balanced): Warfarin | Participants with prior diagnosis of stroke who were newly diagnosed with NVAF and initiated warfarin on the index date and were balanced using sIPTW method. | 1,283 | 11,601 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | PRIMARY | ClinicalTrials.gov |
| Title | Number of Participants With Risk of Major Bleeding at 18 Months: Secondary Prevention (Balanced) Cohorts | ClinicalTrials.gov |
| Description | In this outcome measure, number of participants with risk of major bleeding at 18 months was reported. Major bleeding, was defined as any bleeding which required hospitalization for treatment (the primary reason for the hospitalization was to treat the bleeding). | ClinicalTrials.gov |
| Time frame | 18 months | ClinicalTrials.gov |
| Population | Full analysis set included all eligible participants. Analysis was performed using sIPTW method to balance participant characteristics among reporting groups. sIPTW method created balanced virtual groups and hence overall number of participants analyzed is different from numbers in participant flow (not balanced). | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With Atrial Fibrillation | ClinicalTrials.gov |
| NCT number | NCT05321810 | ClinicalTrials.gov |
| Phases | ClinicalTrials.gov | |
| Conditions | Non-valvular Atrial Fibrillation | ClinicalTrials.gov |
| Interventions | Apixaban, Warfarin | ClinicalTrials.gov |
| Lead sponsor | Pfizer | ClinicalTrials.gov |
| Results first posted | 2024-01-11 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT05321810?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.